Analyst Reco. Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Real-time Estimate Cboe BZX Other stock markets 03:38:52 2024-04-25 pm EDT			5-day change	1st Jan Change
42.62 ^USD	-1.62%		-1.30%	+19.31%

Apr. 17	Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	MT
Mar. 26	Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	Apr. 17	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	Mar. 21	MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating	Mar. 20	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating	Mar. 20	MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating	Mar. 20	MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating	Mar. 20	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating	Mar. 13	MT
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating	Mar. 08	MT
Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target	Mar. 06	MT
Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating	Mar. 04	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating	Feb. 29	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating	Feb. 29	MT
Investors got more clues that rate cuts are imminent	Dec. 19
Evercore ISI Adjusts Price Target on Crinetics Pharmaceuticals to $48 From $41, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $46 From $40, Maintains Outperform Rating	23-09-11	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $45 From $43, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Initiates Coverage on Crinetics Pharmaceuticals With Outperform Rating, $40 Price Target	23-08-31	MT
HC Wainwright Trims Price Target on Crinetics Pharmaceuticals to $33 From $35, Maintains Buy Rating	23-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Analyst Reco.

Filters